'In­spired' by Ipsen's mis­sion, San­dra Sil­vestri joins as next CMO; Ex­i­cure's slide con­tin­ues with CEO, CFO ex­its

Ipsen is wait­ing on an FDA de­ci­sion this sum­mer for what could be the first drug to treat an ul­tra-rare bone dis­ease called fi­brodys­pla­sia os­si­f­i­cans pro­gres­si­va (FOP) — and if all goes well, it will have a new chief med­ical of­fi­cer to take it across the fin­ish line.

San­dra Sil­vestri is join­ing the com­pa­ny from Sanofi on May 5, Ipsen an­nounced ear­li­er this week. An en­docri­nol­o­gist by train­ing, her re­sume boasts long tenures at both Eli Lil­ly and Sanofi, where she was most re­cent­ly the French phar­ma’s se­nior VP and CMO of its Gen­er­al Med­i­cines glob­al busi­ness unit and glob­al head of med­ical af­fairs ca­pa­bil­i­ties at its Cen­tre of Ex­cel­lence and Med­ical Hub.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN